Phase ii trial of intraperitoneal cisplatin and mitoxantrone in patients with persistent ovarian cancer Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Combined Chemotherapy Protocols
  • Ovarian Neoplasms

abstract

  • (1) The combination of IP mitoxantrone and cisplatin has an unacceptable catheter failure rate due to mitoxantrone toxicity; (2) PFS and OS is longer in patients with microscopic rather than macroscopic residual disease; and (3) intraperitoneal platinum-based chemotherapy in patients with very small-volume residual disease may result in improved survival.

publication date

  • April 1999

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1006/gyno.1998.5317

PubMed ID

  • 10094887

Additional Document Info

start page

  • 96

end page

  • 101

volume

  • 73

number

  • 1